

Adam Lundqvist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8959629/publications.pdf>

Version: 2024-02-01

14
papers

370
citations

1040056

9
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

694
citing authors

#	ARTICLE	IF	CITATIONS
1	Socioeconomic inequalities in breast cancer incidence and mortality in Europe—a systematic review and meta-analysis. <i>European Journal of Public Health</i> , 2016, 26, 804-813.	0.3	184
2	Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. <i>PLoS ONE</i> , 2014, 9, e110235.	2.5	34
3	Cost-effectiveness of Screening for Abdominal Aortic Aneurysm in Combination with Medical Intervention in Patients with Small Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2016, 51, 766-773.	1.5	29
4	Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 237-248.	2.1	26
5	Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. <i>Journal of Medical Economics</i> , 2019, 22, 997-1005.	2.1	18
6	Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. <i>Pharmacoeconomics</i> , 2020, 38, 953-969.	3.3	16
7	Direct and indirect costs for anal fistula in Sweden. <i>International Journal of Surgery</i> , 2016, 35, 129-133.	2.7	15
8	Cost-effectiveness of Maintenance Treatment with a Barrier-strengthening Moisturizing Cream in Patients with Atopic Dermatitis in Finland, Norway and Sweden. <i>Acta Dermato-Venereologica</i> , 2016, 96, 173-176.	1.3	12
9	Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. <i>PLoS ONE</i> , 2018, 13, e0191953.	2.5	12
10	Intraductal papillary mucinous neoplasms of the pancreas—a cost-effectiveness analysis of management strategies for the branch-duct subtype. <i>Hpb</i> , 2018, 20, 1206-1214.	0.3	8
11	The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 577-586.	2.5	7
12	Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. <i>Pharmacoeconomics - Open</i> , 2022, , 1.	1.8	5
13	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. <i>Pharmacoeconomics - Open</i> , 2021, 5, 77-88.	1.8	3
14	Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. <i>Applied Health Economics and Health Policy</i> , 2022, , 1.	2.1	1